Buerger's Disease - Pipeline Insight, 2024

This “Buerger’s Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Buerger’s Disease Understanding

Buerger’s Disease: Overview

Buerger’s disease also known as Thromboangiitis obliterans is a rare vascular disease in which blood vessels of the hands and feet become blocked. The affected individual may observe pain as early findings or coldness in the fingers. Later findings include: fingers or toes that appear pale, red, or bluish; sudden severe pain in the hands and feet; skin ulcers; gangrene, and eventual amputation. A diagnosis to check blockage of blood vessels can be done through plethysmography, Doppler ultrasound of the extremity, or Catheter-based x-ray arteriogram. Blood tests for other causes of inflamed blood vessels (vasculitis) and blocked (occlusion of) blood vessels may be done. The goal of treatment for Buerger’s disease is to control symptoms and prevent the disease from getting worse. Total tobacco cessation (smoking, secondhand smoke, and nicotine replacement therapy) is the only treatment that improves symptoms and reduces the risk of amputation, if done before the onset of gangrene or tissue loss. Medication options function as calcium channel blockers, anticoagulants, thrombolytics, prostaglandin analogs, sympathectomy, adrenalectomy, spinal cord stimulators, and omental transfers can be used.

Buerger’s Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Buerger’s Disease pipeline landscape is provided which includes the disease overview and Buerger’s Disease treatment guidelines. The assessment part of the report embraces, in depth Buerger’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Buerger’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Buerger’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Buerger’s Disease.

Buerger’s Disease Emerging Drugs Chapters

This segment of the Buerger’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Buerger’s Disease Emerging Drugs

Mesenchymal stem cell therapy: K-STEMCELLMesenchymal stem cell therapy is a drug candidate that improves or treats ischemic ulcer, etc. caused by Burger’s disease. Vasco Stem, once injected, indirectly vascularizes through the vascular endothelial cell growth factor (VEGF) secreted from VascoStem, and directly restores the damaged tissue. The molecule is in Phase I/II clinical trial for the treatment of Buerger’s Disease. VascoStem has been awarded a rare pharmaceutical product from the Food and Drug Administration (FDA) in May 2016 as a treatment for the berger disease, based on the results of Phase I/II clinical trials in Korea. In addition, the European Medicines Agency (EMA) in March 2017, granted ophan drugdesignation.

ATI-1013: Antidote Therapeutics ATI-1013 is a human, monoclonal antibody that sequesters nicotine in the blood. ATI-1013 was discovered by harnessing the power of the human immune system to generate high affinity antibodies to external antigens. The nicotine-specific mAb program is being supported by an $8.5 million Strategic Alliance grant award from the National Institute on Drug Abuse Division of Therapeutics and Medical Consequences at the National Institutes of Health and has led to the discovery and development of ATI-1013. The drug has also received Orphan Drug Designation from the FDA.

Buerger’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Buerger’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Buerger’s Disease

There are approx. 3+ key companies which are developing the therapies for Buerger’s Disease. The companies which have their Buerger’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Caladrius Biosciences.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Buerger’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Buerger’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Buerger’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Buerger’s Disease drugs.

Buerger’s Disease Report Insights

• Buerger’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Buerger’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Buerger’s Disease drugs?
• How many Buerger’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Buerger’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Buerger’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Buerger’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Antidote Therapeutics
• K-STEMCELL
• Caladrius Biosciences

Key Products

• ATI-1013
• Mesenchymal stem cell therapy
• CLBS 12